The Drug That Looked Real: Simufilam's Pixel-Proofed Promise
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
The Drug That Looked Real: Simufilam's Pixel-Proofed Promise
-
ナレーター：
-
著者：
Hope and doubt collided over a pattern of repeating pixels in a lab image, triggering retractions, sixteen million dollars in federal funding, and trials that enrolled hundreds of Alzheimer's patients - but what did those repeating pixels really mean for the people who took the drug? Which part of simufilam’s story was science, and which was something else?
In this episode, we trace the sequence of events that connected lab images, biomarker shifts, and clinical trials: how FLNA-based theory led to PTI-125 (renamed simufilam), why key experiments all came from a single research group, and how May 2020 biomarker failures were later reported as improvements - but by the same laboratory. What does that chain of evidence reveal about the drug and the trials?
Person: Hoau-Yan Wang
Company: Cassava Sciences
Drug: PTI-125 / simufilam
Funding: $16,000,000 federal
Date of confirmation: November 25, 2024
- Two scientific papers were retracted because the background pixels in western blot images looked too similar.
- Simufilam produced no clinical benefit and the program was discontinued as confirmed by Cassava Sciences on November 25, 2024.
- Sixteen million dollars in federal funding supported early clinical trials beginning after NIH funding in 2018.
- Biomarker results in May 2020 reported failure, then were reported as improved by September 2020, with the later results originating from the same laboratory.
- All key papers linking FLNA dysregulation and simufilam’s mechanism traced back to Hoau-Yan Wang's lab with no independent replication.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません